These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Prophylaxis against rabies. Wilde H; Hemachudha T N Engl J Med; 2005 Apr; 352(15):1608-10; author reply 1608-10. PubMed ID: 15832456 [No Abstract] [Full Text] [Related]
30. Elimination of human rabies in a canine endemic province in Thailand: five-year programme. Kamoltham T; Singhsa J; Promsaranee U; Sonthon P; Mathean P; Thinyounyong W Bull World Health Organ; 2003; 81(5):375-81. PubMed ID: 12862022 [TBL] [Abstract][Full Text] [Related]
31. Potency, sterility and immunogenicity of rabies tissue culture vaccine after reconstitution and refrigerated storage for 1 week. Khawplod P; Wilde H; Tantawichien T; Limusanno S; Tantawichien T; Mitmoonpitak C; Saikasem A; Raksakert S Vaccine; 2002 May; 20(17-18):2240-2. PubMed ID: 12009278 [TBL] [Abstract][Full Text] [Related]
32. A pilot study on intradermal vaccination of Japanese rabies vaccine for pre-exposure immunization. Shiota S; Khawplod P; Ahmed K; Mifune K; Nishizono A Vaccine; 2008 Nov; 26(50):6441-4. PubMed ID: 18804510 [TBL] [Abstract][Full Text] [Related]
33. Antibody persistence, 32 years after post-exposure prophylaxis with human diploid cell rabies vaccine (HDCV). Fayaz A; Simani S; Janani A; Farahtaj F; Biglari P; Howeizi N; Eslami N Vaccine; 2011 May; 29(21):3742-5. PubMed ID: 21458608 [TBL] [Abstract][Full Text] [Related]
34. An economical regimen of human diploid cell strain anti-rabies vaccine for post-exposure prophylaxis. Warrell MJ; Warrell DA; Suntharasamai P; Viravan C; Sinhaseni A; Udomsakdi D; Phanfung R; Xueref C; Vincent-Falquet JC; Nicholson KG; Bunnag D; Harinasuta T Lancet; 1983 Aug; 2(8345):301-4. PubMed ID: 6135830 [TBL] [Abstract][Full Text] [Related]
35. Comparison of saftey and immunogenicity of purified chick embryo cell rabies vaccine (PCECV) and purified vero cell rabies vaccine (PVRV) using the Thai Red Cross intradermal regimen at a dose of 0.1 ML. Madhusudana SN; Sanjay TV; Mahendra BJ; Sudarshan MK; Narayana DH; Giri A; Muhamuda K; Ravi V; Vakil HB; Malerczyk C Hum Vaccin; 2006; 2(5):200-4. PubMed ID: 17035734 [TBL] [Abstract][Full Text] [Related]
36. Intradermal pre-exposure rabies immunisation in New Zealand. Shaw MM; Leggat PA; Williams ML Travel Med Infect Dis; 2006 Jan; 4(1):29-33. PubMed ID: 16887722 [TBL] [Abstract][Full Text] [Related]
37. Intradermal rabies post-exposure prophylaxis can be abridged with no measurable impact on clinical outcome in Cambodia, 2003-2014. Tarantola A; Ly S; Chan M; In S; Peng Y; Hing C; Taing CN; Phoen C; Ly S; Cauchemez S; Buchy P; Dussart P; Bourhy H; Mary JY Vaccine; 2019 Oct; 37 Suppl 1():A118-A127. PubMed ID: 30454946 [TBL] [Abstract][Full Text] [Related]
38. Towards Canine Rabies Elimination in KwaZulu-Natal, South Africa: Assessment of Health Economic Data. Shwiff SA; Hatch B; Anderson A; Nel LH; Leroux K; Stewart D; de Scally M; Govender P; Rupprecht CE Transbound Emerg Dis; 2016 Aug; 63(4):408-15. PubMed ID: 25414096 [TBL] [Abstract][Full Text] [Related]
39. Human diploid-cell rabies vaccine: efficacy of four doses. Hasbahceci M; Kiyan M; Eyol E; Ewalt LC; Lodmell DL Lancet; 1996 Apr; 347(9006):976-7. PubMed ID: 8598794 [No Abstract] [Full Text] [Related]
40. Simplification of Rabies Postexposure Prophylaxis: A New 2-Visit Intradermal Vaccine Regimen. Warrell MJ Am J Trop Med Hyg; 2019 Dec; 101(6):1199-1201. PubMed ID: 31392953 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]